Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases.

Authors:
Van de Wiele VL; Hammer M; Parikh R; Feldman WB; Sarpatwari A and 1 more

Journal:
J Law Biosci

Publication Year: 2022

DOI:
10.1093/jlb/lsac001

PMCID:
PMC8863367

PMID:
35211322

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Law Biosci

Abbreviation: J Law Biosci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Legal

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anticipation in the biosciences and the human right to science.
Boggio A. (2024) - Transparency Score: 2/6
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and …
Pacia DM; Brown BL; Minssen T and 1 more (2024) - Transparency Score: 3/6
Purpose definition as a crucial step for determining the legal basis under the GDPR: implications f…
Becker R; Chokoshvili D; Thorogood A and 5 more (2024) - Transparency Score: 2/6
Cryopreservation and current legal problems: seeking and selling immortality.
Mullock A; Romanis EC. (2023) - Transparency Score: 2/6
Defusing the legal and ethical minefield of epigenetic applications in the military, defense, and s…
Dalpé G; Huerne K; Dupras C and 14 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Funding Mr Van de Wiele’s work was partially supported by a grant from Association for Accessible Medicines from 2019 to 2020. Dr Kesselheim and Dr Sarpatwari’s work was supported by Arnold Ventures. Dr Feldman’s work is supported by the National Institutes of Health and the FDA Sentinel Initiative. The funders had no role in the preparation, review, or approval of the manuscript or the decision to submit the manuscript for publication."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025